Contradictory cognitive capacities among substance-abusing patients with schizophrenia: A meta-analysis

Schizophrenia Research

Volumn 100, Issue 1-3, 2008, Pages 242-251

  Potvin, Stéphane ^a,b   Joyal, Christian C ^a,c,d   Pelletier, Julie ^a   Stip, Emmanuel ^a  

^a CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

^b UNIVERSITÉ DE SHERBROOKE   (Canada)

^c Institut Philippe Pinel de Montreal   (Canada)

^d UNIVERSITÉ DU QUÉBEC À TROIS RIVIÈRES   (Canada)

Author keywords

Cognition; Meta analysis; Neuropsychology; Schizophrenia; Substance abuse

Indexed keywords

CANNABIS;

AGE DISTRIBUTION; ALCOHOL CONSUMPTION; ARTICLE; COGNITION; COMORBIDITY; DISEASE SEVERITY; HUMAN; MENTAL PERFORMANCE; MENTAL TASK; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; PROBLEM SOLVING; PSYCHOLOGIC TEST; PSYCHOSIS; SCHIZOPHRENIA; SUBSTANCE ABUSE; VISUAL MEMORY;

ADULT; AGE FACTORS; AGED; COGNITION DISORDERS; COMORBIDITY; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; SEX FACTORS; STREET DRUGS; SUBSTANCE-RELATED DISORDERS;

EID: 39849101201     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2007.04.022     Document Type: Article

References (64)

1. Addington J., and Addington D. Substance abuse and cognitive functioning in schizophrenia. J. Psychiatry Neurosci. 2 (1997) 99-104
2. Allen D.N., and Remy C.J. Neuropsychological deficits in patients with schizophrenia and alcohol dependence. Arch. Clin. Neuropsychol. 15 (2000) 762-763
3. Allen D.N., Goldstein G., and Aldarondo F. Neurocognitive dysfunction in patients diagnosed with schizophrenia and alcoholism. Neuropsychology 13 (1999) 62-68
4. Allen D.N., Goldstein G., Forman S.D., Kashavan M.S., van Kammen D.P., and Sanders R.D. Neurologic examination abnormalities in schizophrenia with and without a history of alcohol. Neuropsychiatry Neuropsychol. Behav. Neurol. 13 (2000) 184-187
5. Andreasen N.C., Flaum M., Swayze II V.W., Tyrrell G., and Arndt S. Positive and negative symptoms in schizophrenia. A critical reappraisal. Arch. Gen. Psychiatry 47 (1990) 615-621
6. Arndt S., Tyrrell G., Flaum M., and Andreasen N.C. Comorbidity of substance abuse and schizophrenia: the role of pre-morbid adjustment. Psychol. Med. 22 (1992) 379-388
7. Barnes T.R.E., Mutsatsa S.H., Hutton S.B., Watt H.C., and Joyce E.M. Comorbid substance use and age at onset of schizophrenia. Br. J. Psychiatry 188 (2006) 237-242
8. Bilder R.M., Goldman R.S., Robinson D., Reiter G., Bell L., Bates J.A., Pappadopulos E., Willson D.F., Alvir J.M.J., Woerner M.G., Geisler S., Kane J.M., and Lieberman J.A. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am. J. Psychiatry 157 (2000) 549-559
9. Borenstein M., and Rothstein H. Comprehensive Meta-analysis: a computer program for research synthesis (1999), Biostat, Englewood, NJ
10. Bowie C.R., Serper M.R., Riggio S., and Harvey P.D. Neurocognition, symptomatology, and functional skills in older alcohol-abusing schizophrenia patients. Schizophr. Bull. 31 (2005) 175-182
11. Breakey W.R., Goodell H., Lorenz P.C., and McHugh P.R. Hallucinogenic drugs as precipitants of schizophrenia. Psychol. Med. 4 (1974) 255-261
12. Buchanan R.W., Kirkpatrick B., Heinrichs D.W., and Carpenter W.T. Clinical correlates of the deficit syndrome of schizophrenia. Am. J. Psychiatry 147 (1990) 290-294
13. Buckley P.B., Thompson P., Way L., and Meltzer H.Y. Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for Clozapine therapy. Am. J. Pschiatry 151 (1994) 385-389
14. Carey K.B., Carey M.P., and Simons J.S. Correlates of substance use disorder among psychiatric outpatients: focus on cognition, social role functioning, and psychiatric status. J. Nerv. Ment. Dis. 191 (2003) 300-308
15. Cleghorn J.M., Kaplan R.D., Szechtman B., Szechtman H., Brown H.G., and Franco S. Substance abuse and schizophrenia: effect on symptoms but not on neurocognitive function. J. Clin. Psychiatry 52 (1991) 26-30
16. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. (1988), Erlbaum, Hillsdale, NJ
17. Copersino M.L., Serper M.R., Vadhan N., Goldberg B., Richarme D., Chou J.C.Y., Stitzer M., and Cancro R. Cocaine craving and attentional bias in cocaine-dependent schizophrenic patients. Psychiatry Res. 128 (2004) 209-218
18. In: Cooper H., and Hedges L.V. (Eds). Handbook of Research Synthesis (1994), Russell Sage Foundation, New York
19. Cooper L., Liberman D., Tucker D., Neuchterlein K.H., Tsuang J., and Barnett H.L. Neurocognitive deficits in the dually diagnosed with schizophrenia and cocaine abuse. Psychiatr. Rehabil. Skills 3 (1999) 231-245
20. DerSimonian R., and Laird N. Meta-analysis in clinical trials. Control. Clin. Trials 7 (1986) 177-188
21. Dixon L., Haas G., Weiden P., Sweeney J., and Frances A. Acute effects of drug abuse in schizophrenic patients: clinical observations and patients' self-reports. Schizophr. Bull. 16 (1990) 69-79
22. Dixon L., Haas G., Weiden P.J., Sweeney J., and Frances A.J. Drug abuse in schizophrenic patients : clinical correlates and reasons for use. Am. J. Psychiatry 148 (1991) 224-230
23. Fenton W.S., and McGlashan T.H. Natural history of schizophrenia subtypes. II. Positive and negative symptoms and long-term course. Arch. Gen. Psychiatry 48 (1991) 978-986
24. Goldstein J.M., Seidman L.J., Goodman J.M., Koren D., Lee H., Weintraub S., and Tsuang M.T. Are there sex differences in neuropsychological functions among patients with schizophrenia. Am. J. Psychiatry 155 (1998) 1358-1364
25. Green M.F., Nuechterlein K.H., Gold J.M., Barch D.M., Cohen J., Essock S., Fenton W.S., Goldberg T.E., Heaton R.K., Keefe R.S.E., Kern R.S., Stover E., Weinberger D.R., Zalcman S., and Marder S.R. Approaching a concensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol. Psychiatry 56 (2004) 301-307
26. Gupta S., Rajaprabhakaran P., Arndt S., Flaum M., and Andreasen N. Premorbid adjustment as a predictor of phenomenological and neurobiological indices in schizophrenia. Schizophr. Res. 16 (1995) 189-197
27. Herman M. Neurocognitive functioning and quality of life among dually-diagnosed and non-substance abusing schizophrenia in patients. Int. J. Ment. Health Nursing 13 (2004) 282-291
28. Johnson B.T. DSTAT: software for the meta-analytic review of research literatures (1989), Lawrence Erlbaum Associates, Hillsdale, NJ
29. Joyal C.C., Hallé P., Lapierre D., and Hodgins S. Drug abuse and/or dependence and better neuropsychological performance in patients with schizophrenia. Schizophr. Res. 63 (2003) 297-299
30. Kavanagh D.J., McGrath J., and Saunders J.B. Substance misuse in patients with schizophrenia: epidemiology and management. Drugs 62 5 (2002) 743-755
31. Kelley M.E., Gilbertson M., Mouton A., and van Kammen D.P. Deterioration in premorbid functioning in schizophrenia: a developmental model of negative symptoms in drug-free patients. Am. J. Psychiatry 149 (1992) 1543-1548
32. Kirkpatrick B., Amador X.F., Flaum M., Yale S.A., Gorman J.M., Carpenter Jr. W.T., Tohen M., and McGlashan T. The deficit syndrome in the DSM-IV Field Trial: I. Alcohol and other drug abuse. Schizophr. Res. 20 (1996) 69-77
33. Krysta K., Krupka-Matsuszczyk I., and Klaslik A. Impact of drug abuse on cognitive functioning in schizophrenia. Eur. Neuropsychopharmacol. 15 Suppl 3 (2005) S579
34. Kumra S., Thaden E., DeThoma C., and Kranzler H. Correlates of substance abuse in adolescents with treatment-refractory schizophrenia and schizoaffective disorder. Schizophr. Res. 73 (2005) 369-371
35. In: Lezak M.D., Howieson D.B., and Loring D.W. (Eds). Neuropsychological Assessment. 4th ed. (1994), Oxford University Press, New York
36. Liraud F., and Verdoux H. Impact neuropsychologique de l'abus de substances psychoactives dans les troubles psychotiques et de l'humeur. Encephale 28 (2002) 160-168
37. McCleery A., Addington J., and Addington D. Substance misuse and cognitive functioning in early psychosis: a 2 year follow-up. Schizophr. Res. 88 (2006) 187-191
38. Merriam A.E., Kay S.R., Opler L.A., Kushner S.F., and van Praag H.M. Neurological signs and the positive-negative dimension in schizophrenia. Biol. Psychiatry 28 (1990) 181-192
39. Mohamed S., Bondi M.W., Kasckow J.W., Golshan S., and Jeste D.V. Neurocognitive functioning in dually diagnosed middle aged and elderly patients with alcoholism and schizophrenia. Int. J. Geriatr. Psychiatry 21 8 (2006) 711-718
40. Mueser K.T., Yarnold P.R., Levinson D.F., Singh H., Bellack A.S., Kee K., Morrison R.L., and Yadalam K.G. Prevalence of substance abuse in schizophrenia : demographic and clinical correlates. Schizophr. Bull. 16 (1990) 31-56
41. Mueser K.T., Drake R.E., and Wallach M.A. Dual diagnosis: a review of etiological theories. Addict. Behav. 23 (1998) 717-734
42. Nixon S.J., Hallford G.H., and Tivis R.D. Neurocognitive function in alcoholic, schizophrenic, and dually diagnosed patients. Psychiatry Res. 64 (1996) 35-45
43. Nuechterlein K.H., Barch D.M., Gold J.M., Goldberg T.E., Green M.F., and Heaton R.K. Identification of separable cognitive factors in schizophrenia. Schizophr. Res. 72 1 (2004) 29-39
44. Pencer A., and Addington J. Substance use and cognition in early psychosis. J. Psychiatry Neurosci. 8 (2003) 48-54
45. Potvin S., Briand C., Prouteau A., Bouchard R.H., Lipp O., Lalonde P., Nicole L., Lesage A., and Stip E. CANTAB explicit memory is less impaired in addicted schizophrenia patients. Brain Cogn. 59 (2005) 38-42
46. Ramirez B.G., Blazquez C., Gomez del Pulgar T., Guzman M., and de Ceballos M.L. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J. Neurosci. 25 (2005) 1904-1913
47. Regier D.A., Farmer M.E., Rae D.S., Locke B.Z., Keith S.J., Judd L.L., and Goodwin F.K. Comorbidity of mental disorders with alcohol and other drug abuse. JAMA 264 (1990) 2511-2518
48. Ries R.K., Russo J., Wingerson D., Snowden M., Comtois K.A., Srebnik D., and Roy-Byrne P. Shorter hospital stays and more rapid improvement among patients with schizophrenia and substance disorders. Psychiatr. Serv. 51 (2000) 210-215
49. Ritzler B.A., Strauss J.S., Vanord A., and Kokes R.F. Prognostic implications of various drinking patterns on psychiatric patients. Am. J. Psychiatry 134 (1977) 546-549
50. Salyers M.P., and Mueser K.T. Social functioning, psychopathology, and medication side effects in relation to substance use and abuse in schizophrenia. Schizophr. Res 48 (2001) 109-123
51. Sanguineti V.R., and Samuel S.E. Comorbid substance abuse and recovery from acute psychiatric relapse. Hospital and Community Psychiatry 44 (1993) 1073-1076
52. Scheurich A. Neuropsychological functioning and alcohol dependence. Curr. Opin. Psychiatry 18 (2005) 319-323
53. Serper M.R., Bergman A., Copersino M.L., Chou J.C.Y., Richarme D., and Cancro R. Learning and memory impairment in cocaine-dependent and comorbid schizophrenic patients. Psychiatry Res. 93 (2000) 21-32
54. Serper M.R., Copersino M.L., Richarme D., Vadhan N., and Cancro R. Neurocognitive functioning in recently abstinent, cocaine-abusing schizophrenic patients. J. Subst. Abuse 11 (2000) 205-213
55. Sevy S., Kay S.R., Opler L., and van praag H.M. Significance of cocaine history in schizophrenia. J. Nerv. Ment. Dis. 178 (1990) 642-648
56. Sevy S., Robinson D.G., Solloway S., Alvir J.M., Woerner M.B., Bilder R., Goldman R., Lieberman J., and Kane J. Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder. Acta Psychiatr. Scand. 104 (2001) 367-374
57. Silverstein M.L., Mavrolefteros G., and Close D. Premorbid adjustment and neuropsychological performance in schizophrenia. Schizophr. Bull. 28 (2002) 157-165
58. Smelson D.A., Davis C.W., Di Pano R., Johnson V., Losonczy M.F., and Ziedonis D. Executive and motor skill functioning among cocaine-dependent schizophrenics. J. Nerv. Ment. Dis. 190 (2002) 200-202
59. Smelson D.A., Davis C.W., Eisenstein N., Engelhart C., Williams J., Losonczy M.F., and Ziedonis D. Cognitive disparity in schizophrenics with and without cocaine dependency. J. Subst. Abuse Treat. 24 (2003) 75-79
60. Stirling J., Lewis S., Hopkins R., and White C. Cannabis use prior to first onset psychosis predicts spared neurocognition at 10-year follow-up. Schizophr. Res. 75 (2005) 135-137
61. Swofford C.D., Scheller-Gilkey G., Miller A.H., Woolwine B., and Mance R. Double jeopardy: schizophrenia and substance use. Am. J. Drug Alcohol Abuse 26 (2000) 343-353
62. Thoma R.J., Hanlon F.M., Miller G.A., Huang M., Weisend M.P., Sanchez F.P., Waldorf A.V., Jones A., Smith A., Formoso M.J., and Canive J.M. Neuropsychological and sensory gating deficits related to remote alcohol abuse history in schizophrenia. J. Int. Neuropsychol. Soc. 12 (2006) 34-44
63. Tsuang M.T., Simpson J.C., and Zronfonl Z. Subtypes of drug abuse with psychosis. Demographic characteristics, clinical features, and family history. Arch. Gen. Psychiatry 38 (1982) 141-147
64. Zisook S., Heaton R., Moranville J., Kuck J., Jernigan T., and Braff D. Past substance abuse and clinical course of schizophrenia. Am. J. Psychiatry 149 (1992) 552-553